Wahab Sasha H, Simpson Joseph R, Michalski Jeff M, Mansur David B
Department of Radiation Oncology, Washington University School of Medicine, 4921 Parkview Place, Lower Level, St. Louis, MO 63110, USA.
J Neurooncol. 2007 May;83(1):85-9. doi: 10.1007/s11060-006-9310-2. Epub 2007 Jan 6.
A retrospective study was performed to evaluate the long term efficacy and safety of post-operative radiation therapy in the management of spinal canal ependymoma at our institution.
Between 1954 and 1997, 22 patients with spinal canal ependymoma were treated with post-operative radiotherapy at our institution. The median age at diagnosis was 34.7 years (range 9.8-56.1 years). All patients underwent open biopsy with histologic diagnosis: 13 patients (59%) had ependymoma (WHO Grade II) and 9 patients (41%) had myxopapillary ependymoma (WHO Grade I). The median tumor size was 4.0 cm (range 1.5-15.0 cm). Twenty patients received subtotal resection and 2 patients received gross-total resection. Median radiation dose was 45.0 Gy.
The median follow up for surviving patients was 11.4 years (range 0.6-37.0 years). An 80% progression-free-survival (PFS) was observed for all patients at 5-, 10- and 15-year endpoints. All recurrences were within 3 years of treatment. The 5-, 10- and 15-year overall-survivals (OS) for all patients were 85%, 78% and 64%, respectively. Patients with tumors larger than 6.0 cm at time of presentation demonstrated 5- and 10-year PFS of 58.3% compared to 92.3% for patients with tumors 6.0 cm or smaller (P = 0.047). There was no significant correlation between tumor size and OS.
Post-operative radiation after subtotal resection is safe and offers durable tumor control and long term patient survival.
进行一项回顾性研究,以评估我院术后放射治疗在椎管内室管膜瘤治疗中的长期疗效和安全性。
1954年至1997年间,我院对22例椎管内室管膜瘤患者进行了术后放射治疗。诊断时的中位年龄为34.7岁(范围9.8 - 56.1岁)。所有患者均接受了开放活检并获得组织学诊断:13例患者(59%)为室管膜瘤(世界卫生组织二级),9例患者(41%)为黏液乳头型室管膜瘤(世界卫生组织一级)。肿瘤中位大小为4.0厘米(范围1.5 - 15.0厘米)。20例患者接受了次全切除,2例患者接受了全切除。中位放射剂量为45.0 Gy。
存活患者的中位随访时间为11.4年(范围0.6 - 37.0年)。在5年、10年和15年的随访终点时,所有患者的无进展生存率(PFS)为80%。所有复发均发生在治疗后3年内。所有患者的5年、10年和15年总生存率(OS)分别为85%、78%和64%。就诊时肿瘤大于6.0厘米的患者5年和10年PFS为58.3%,而肿瘤小于或等于6.0厘米的患者为92.3%(P = 0.047)。肿瘤大小与OS之间无显著相关性。
次全切除术后的放射治疗是安全的,能有效控制肿瘤并使患者长期存活。